Annette Bunge and her research group have had the central theme of mathematically modeling the dermal absorption process. Most of the research focus has been on estimating dermal absorption for the purpose of risk assessment, for exposure scenarios in the environment and in the occupational setting. Her work is the basis for the United States Environmental Protection Agency's estimations for dermal absorption from contaminated water. It is also the basis of the dermal absorption estimates used in determining if chemicals should be assigned a ‘skin notation' for potential systemic toxicity following occupational skin exposure. The work is truly translational in that it started with mathematical theory, is validated with preclinical and human experiments, and then is used in guidelines to protect human health. Her valued research has also extended into the topical drug bioavailability and bioequivalence assessment field.

1.
Krueger GG, Wojciechowski ZJ, Burton SA, Gilhar A, Huether SE, Leonard LG, Rohr UD, Petelenz TJ, Higuchi WI, Pershing LK: The development of a rat/human skin flap served by a defined and accessible vasculature on a congenitally athymic (nude) rat. Fundam Appl Toxicol 1985;5:S112-S121.
2.
Wojciechowski Z, Pershing LK, Huether S, Leonard L, Burton SA, Higuchi WI, Krueger GG: An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. J Invest Dermatol 1987;88:439-446.
3.
Cleek RL, Bunge AL: A new method for estimating dermal absorption from chemical exposure. 1. General approach. Pharm Res 1993;10:497-506.
4.
Bunge AL, Cleek RL: A new method for estimating dermal absorption from chemical exposure. 2. Effect of molecular weight and octanol-water partitioning. Pharm Res 1995;12:88-95.
5.
Bunge AL, Cleek RL, Vecchia BE: A new method for estimating dermal absorption from chemical exposure. 3. Compared with steady-state methods for prediction and data analysis. Pharm Res 1995;12:972-982.
6.
Blank IH, Scheuplein RJ, MacFarlane DJ: Mechanism of percutaneous absorption. 3. The effect of temperature on the transport of non-electrolytes across the skin. J Invest Dermatol 1967;49:582-589.
7.
Scheuplein RJ: Mechanism of percutaneous adsorption. I. Routes of penetration and the influence of solubility. J Invest Dermatol 1965;45:334-346.
8.
Scheuplein RJ: Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J Invest Dermatol 1967;48:79-88.
9.
Scheuplein RJ: Percutaneous absorption after twenty-five years: or ‘old wine in new wineskins'. J Invest Dermatol 1976;67:31-38.
10.
Scheuplein RJ, Blank IH: Permeability of the skin. Physiol Rev 1971;51:702-747.
11.
Scheuplein RJ, Blank IH: Mechanism of percutaneous absorption. IV. Penetration of nonelectrolytes (alcohols) from aqueous solutions and from pure liquids. J Invest Dermatol 1973;60:286-296.
12.
Scheuplein RJ, Blank IH, Brauner GJ, MacFarlane DJ: Percutaneous absorption of steroids. J Invest Dermatol 1969;52:63-70.
13.
Scheuplein RJ, Ross LW: Mechanism of percutaneous absorption. V. Percutaneous absorption of solvent deposited solids. J Invest Dermatol 1974;62:353-360.
14.
Chandrasekaran SK, Campbell PS, Michaels AS: Effect of dimethyl sulfoxide on drug permeation through human skin. AIChE J 1977;23:810-816.
15.
Chandrasekaran SK, Michaels AS, Campbell PS, Shaw JE: Scopolamine permeation through human skin in vitro. AIChE J 1976;22:828-832.
16.
Michaels AS, Chandrasekaran SK, Shaw JE: Drug permeation through human skin. Theory and in vitro experimental measurement. AIChE J 1975;21:985-996.
17.
Reddy MB, Stinchcomb AL, Guy RH, Bunge AL: Determining dermal absorption parameters in vivo from tape strip data. Pharm Res 2002;19:292-298.
18.
Navidi W, Hutchinson A, N'Dri-Stempfer B, Bunge A: Determining bioequivalence of topical dermatological drug products by tape-stripping. J Pharmacokinet Pharmacodyn 2008;35:337-348.
19.
N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL: Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res 2009;26:316-328.
20.
N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL: Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res 2008;25:1621-1630.
21.
Stinchcomb AL, Pirot F, Touraille GD, Bunge AL, Guy RH: Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. Pharm Res 1999;16:1288-1293.
22.
Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH: Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci USA 1997;94:1562-1567.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.